New Atomwise offshoot X-37 raises $14.5M to shepherd AI-designed drugs

molecule
In addition to targets in autoimmune disease, cancer and coagulation, X-37 will use Atomwise’s AI platform to develop other leads and targets with the goal of raising them to a point where they can be acquired or partnered with a pharma company. (University of California, San Francisco)

Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals with pharma industry partners.

Dubbed X-37, the new firm will maintain a flexible LLC structure that will house each development program within its own virtual subcompany. This will allow X-37 to divest individual properties in the future while maintaining its parent organization and team, the company said.

And to kick things off, X-37 is debuting with a $14.5 million series A round to fund operations and early development, starting in autoimmune diseases, cancer and anticoagulation. It began research work in 2018 and aims to have novel candidates ready to begin human testing by 2022.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

"We are thrilled with the progress we have made to date and we are looking forward to moving a set of important new drugs into development,” X-37 CEO and co-founder David Collier said in a statement.

RELATED: Atomwise to screen 10B compounds for potential childhood cancer therapies

“With this financing, we have the ability to progress multiple discovery and development programs,” Collier said. “Our investors have been a huge help in the genesis of X-37, and we look forward to working closely with them going forward.” The series A round was led by DCVC Bio, alongside participation from Alpha Intelligence Capital and Hemi Ventures.

In addition to targets such as ZAP-70 in autoimmune disease, PIM3 and SHP2 in cancer and coagulation factor XIIa, X-37 will use Atomwise’s AI platform to design and develop other drug leads and targets with the goal of bringing them to a point where they can be acquired or partnered with a pharma company for the remainder of their development and commercialization.

"X-37 represents an opportunity to bring new drugs to market very quickly, for challenging targets that have repeatedly stumped pharma and are in dire need of advancement,” said Atomwise founder and CEO Abraham Heifets.

RELATED: Special Report—The top AI lighthouse projects to watch in biopharma

“We identified the team of drug developers at Velocity Pharmaceutical Development as ideal partners for Atomwise because of their experience in target selection and development of drug leads beyond the initial discovery stage,” said Kiersten Stead of DCVC Bio, who joins X-37’s board. “The progress of the combined teams at X-37 has been superb.”

Suggested Articles

Novartis has teamed up with smart inhaler developer Propeller Health to co-package and ship its digital medication-tracking platform.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.